PRECIPIO INC (PRPO)
US74019L6020 - Common Stock
PRPO Stock Earnings: Precipio Beats EPS, Misses Revenue for Q4 2023
PRPO stock results show that Precipio beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Precipio Announces Year end 2023 Shareholder Update Call
Conference Call to be held on April 1st, 2024 at 5:00 PM EDT...
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Company continues to make strides towards breakeven...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a...
Precipio’s Q4 cash burn from operations drops below $100K for full quarter (NASDAQ:PRPO)
Precipio, a specialty cancer diagnostics company, reduces cash burn by over 90% in Q4-2023, bringing them closer to breakeven, but cautions Q1-2024 may not...
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Results clearly demonstrate the business’s ability to reach breakeven in the near future ...
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
First order for IV-Cell placed by Major Japanese Laboratory...
Precipio Announces Christina Valauri joins the Board of Directors
Douglas Fisher, MD will step down as Director, and remain as a board observer...
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and...
Precipio Announces Q3-2023 Shareholder Update Call
Conference Call to be held on November 20th, 2023 at 5:00 PM EST...
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
28% Revenue Increase Is Major Step Toward Company Breakeven...
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakeven...
Precipio continues to sign new HemeScreen customers (NASDAQ:PRPO)
Precipio announces new customer orders expected to bring Q4 HemeScreen revenues to $1.2M, moving closer to cash flow breakeven.
Precipio Continues to Sign New HemeScreen™ Customers
New customer orders received in Q3 exceed $1M annualized revenue...
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M...
Precipio announces 1-for-20 reverse stock split to regain Nasdaq compliance (NASDAQ:PRPO)
Specialty cancer diagnostics company Precipio implements reverse stock split to regain Nasdaq compliance, with shares expected to trade on a split-adjusted basis. PRPO -3% premarket.
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
Company announces 1-for-20 reverse stock split...
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
Company continues to make strides towards profitability...
Precipio Announces Q2-2023 Shareholder Update Call
Conference Call to be held on August 17, 2023 at 5:00 PM EST...
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Advanced panel already generating six-figure pre-orders ...
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
These efficiencies plus revenue growth expected to continue the positive momentum...
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Revenue growth and customer pipeline advance the Company towards breakeven...
Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling...
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
New panel will enable rapid, precise genetic profiling of patients with deadly disease...
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered...
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3...
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care...